Century Therapeutics, Inc. · NASDAQ:IPSC
Century Therapeutics — Investor Presentation (January 2026)
36 slides from Century Therapeutics's investor presentation, Jan 8, 2026
Slide 1: Unlocking the Value of our Pipeline for T1D
Unlocking the Value of our Pipeline for T1D January 2026
Slide 2: Forward-looking statements
2 Forward-looking statements This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this presentation, other than statements of historical facts
Slide 3: Century Therapeutics Today
Cell Foundry and Allo-Evasion Technology High Impact Programs Focused on Execution Century Therapeutics Today © 2025 3 Cell foundry generates fully functional cells at scale • Key developmental insights allow directed differentiation of cells that function like primary cells, such as beta Islet cell
Slide 4: Century pipeline spans cell types and targets in autoimmune disease and cancer
4 Product Targets Indications Research IND-enabling Clinical Phase 1 Phase 2 Phase 3 CNTY-101 iNK (Allo-Evasion 1.0) CD19 B-cell-mediated autoimmune diseases CNTY-308 αβ iT (Allo-Evasion 5.0) CD19 B-cell-mediated autoimmune diseases CNTY-813 Beta Islet cells (Allo-Evasion 5.0) Beta Islet Transplanta
Slide 5: Century Therapeutics
CENTURY THERAPEUTICS
Slide 6: Century is a leader in immune evasion engineering
6 Continued evolution to enhance holistic protection from major immunity pathways Century is a leader in immune evasion engineering Allo-Evasion 1.0 Deletion of HLA-I Deletion of HLA-II Insertion of HLA-E Protection from: Native T-cells Native NK-cells Humoral immunity CNTY-101 Deletion of HLA-I Del
Slide 7: Allo-Evasion 5.0: CD300a TASR ligand protects from host NK cells
7 Allo-EvasionTM 5.0: The CD300a TASR ligand has been shown to provide broad protection from host NK cells Male Female <50 >50 Gender Age Ethni-city CMV Caucasian Other African American Hispanic Negative Positive N = 45 PBMC Donors 0.01 0.1 1 0 0 .0 1 0 .1 1 0 25 50 75 100 0 E:T Ratio T Cell Surviva
Slide 8: Allo-Evasion 5.0: IgG degrading enzyme protects from humoral immunity
8 Immunoglobulin degrading protease As a result, Century’s T cells have been shown to be protected from rejection in preclinical CDC, ADCC and ADCP assays Century T cells have been shown to stably express IDP, an enzyme that cleaves off IgGs below the hinge, releasing the Fc fragment Allo-EvasionTM
Slide 9: Type 1 Diabetes Program
Type 1 Diabetes Program
Slide 10: Significant unmet need in Type 1 Diabetes (T1D)
10 Significant unmet need in Type 1 Diabetes (T1D) Despite insulin therapy, people living with T1D face a high risk of life-limiting complications ~9 million people worldwide living with T1D1 Lifetime economic burden of T1D (US) estimated at~$813 billion2 T1D is associated with serious comorbidities
Slide 11: Beta Islet cell transplantation provides potentially curative therapy in T1D
11 Beta Islet cell transplantation provides potentially curative therapy in T1D In T1D, beta cells are destroyed Healthy islet beta cells produce insulin (green) In T1D, beta cells are destroyed In T1D, beta cells can be replaced Current approaches have limitations • Major complications in all allog
Slide 12: CNTY-813: Century's Beta Islets with Allo-Evasion 5.0
12 CNTY-813: Century’s Beta Islets with Allo-Evasion 5.0 Uniquely positioned to potentially deliver a successful T1D cell replacement therapy • Glucose control in patients is important for resolving disease and reducing consequences of uncontrolled glucose • Immune suppression has significant long-t
Slide 13: CNTY-813 Scalable Generation of Beta Islets with Allo-Evasion 5.0
13 A fully scalable, bioreactor-enabled differentiation process yields mature, functional beta Islets from engineered iPSCs Clinical candidate selected with Century’s Allo-Evasion 5.0 to protect cells from immune rejection In vitro and in vivo data support potential to provide functional cure withou
Slide 14: Generation of Beta Islets with a 29 day, defined, multi-stage process
14 iPSC Definitive Endoderm Primitive Gut Tube Pancreatic Progenitor I Pancreatic Progenitor II Endocrine β Cell Generation of Beta Islets with a 29 day, Defined, Multi-stage Process Adapted to a Scalable Bioreactor Suspension System iPSC DE PGT PP1 PP2 EN β Stage 1 Stage 2 Stage 3 Stage 4 Stage 5 S
Slide 15: Beta-islet differentiation process is reproducible across batches
15 Century beta-islet differentiation process is reproducible across batches High Purity Throughout the Differentiation Stage 1: Definitive Endoderm Stage 4: Pancreatic Endoderm Stage 6: Islet Endocrine Stage 6: Beta Cell Success Criteria: set by literature review of necessary purity to ensure a saf
Slide 16: CNTY-813 Beta Islets are highly potent
16 CNTY-813 Beta Islets are highly potent Potency Total Insulin Content Glucose-Stimulated Insulin Secretion Stimulation Index iPSC-Beta Islets Primary Islets 0 10000 20000 30000 40000 uIU Insulin/ 1E6 Cells 2mM Glucose 20mM Glucose iPSC-Beta Islets Primary Islets 0 5 10 15 Glucose Stimualtion Index
Slide 17: CNTY-813 comprises terminally differentiated endocrine cells
17 CNTY-813 comprises terminally differentiated endocrine cells Cell Cycle Analysis of Stage 6 CNTY-813 cells Cell Cycle Progression Analysis by Differentiation Stage Diff. Stage: iPSC 1 2 3 4 5 6 Post-mitotic β-islets with no cell proliferation MKI67 gene expression Cell cycle stage Source: Company
Slide 18: CNTY-813 rapidly restored normoglycemia in STZ-rendered T1D mice
18 CNTY-813 Beta Islets rapidly restored normoglycemia in STZ-rendered T1D mice Century Beta Islets Persisted and Controlled Glucose for >4 Months Non-Fasted Blood Glucose Century iPSC Beta Islets (unedited) Century iPSC Beta Islets with Allo-Evasion 5.0 Mean ± SEM -20 0 20 40 60 80 100 120 140 0 10
Slide 19: CNTY-813 restores normoglycemia upon Glucose Tolerance Test
19 CNTY-813 observed to restore normoglycemia upon a Glucose Tolerance Test (GTT) Upon a GTT, normoglycemia is rescued within 60 minutes in both Unedited and Allo 5.0 Beta islet txp mice 12-week 0 10,000 20,000 30,000 40,000 AUC Diabetic Control: n=5 Unedited CNTY Beta Islets: n=3 Allo 5.0 CNTY Beta
Slide 20: CNTY-813 beta islet grafts show no outgrowths at 16 weeks
20 CNTY-813 beta islet grafts observed to show no outgrowths at 16 weeks CNTY-813 iPSC Beta Islets High Endocrine Purity >95% CHGA 16 weeks post-transplant Well defined beta islet graft Source: Company data on file
Slide 21: CNTY-813 grafts comprised of endocrine cells with no outgrowths
21 CNTY-813 grafts were observed to be comprised of endocrine cells with no evidence of outgrowths • 5M islets injected into the murine kidney capsule – STZ treatment abrogated mouse insulin production – Mouse was normoglycemic within 30 days post-infusion • Treated kidney harvested at post-infusion
Slide 22: Allo-Evasion 5.0 protects CNTY-813 Beta Islets
22 Allo-Evasion 5.0 protects CNTY-813 Beta Islets Protection of Beta Islets • NK protection • ADCC protection Allo-Evasion 5.0 on Beta Islets • Elimination of HLA-I and II expression • Confirmed expression of Transgenes Count Normalized to Mode HLA Class I HLA Class II IdeS CD300a-TASR T Cell Evasio
Slide 23: Scalable manufacturing of cryopreserved Beta Islets
23 Scalable manufacturing of cryopreserved Beta Islets Suspension-Based iPSC Differentiation to Cryopreserved Beta Islets Permit Scalable Clinical Manufacturing Scalable iPSC Differentiation Platform Cryopreserved Century Beta Islets Single Dose Clinical Administration 3-80L+ PBS (or Stirred Tank) B
Slide 24: Autoimmune Disease Programs
Autoimmune Disease Programs
Slide 25: Addressing unmet need in autoimmunity with allogeneic CAR iT and CAR iNK cells
25 Addressing significant unmet need in autoimmunity with allogeneic CAR iT and CAR iNK cells • Limited but encouraging POC data2 with CAR-NK therapy support continued development in autoimmune disease • CARAMEL IST with CNTY-101 currently enrolling patients across four indications • Autologous CAR
Slide 26: CNTY-308 CD4+/CD8+ αβ iT-cell with Allo-Evasion 5.0
CNTY-308 CD4+/CD8+ αβ iT-cell with Allo-Evasion 5.0
Slide 27: CNTY-308 is an iPSC-derived CD19-targeted CAR-iT
27 CNTY-308 is an iPSC-derived CD19-targeted CAR-iT intended for B-cell-mediated disease CNTY-308 CD4+/CD8+ αβ iT-cell • CD19-targeted CAR to target B-cells for cytotoxic depletion – 4-1BB and CD3z co-stim domain to stimulate expansion on target engagement • Allo-Evasion 5.0 edits designed to includ
Slide 28: Century iPSC-derived CAR-αβT cells comparable to primary CAR-T cells
28 Function 1’ CAR-T CNTY-308 IL-2 secretion (pg/mL) ~3,000 ~2,000 Requires exogenous IL-2/IL-15 No No Repeat killing (rounds) >10 >10 Persistence in blood (days) 32 32 Tumor control after rechallenge (in vivo) Yes Yes CNTY–308 and 1’ CAR-T • Self-supports with own target-mediated IL-2 • High functi
Slide 29: iPSC-CAR-T cells controlled tumors and persisted in animal studies
29 In preclinical animal studies, Century iPSC-CAR-T cells controlled tumors, persisted for ≥1 month, and retained cytotoxic capacity upon rechallenge • Disseminated Nalm6 model (1e5 cells infused) • Effectors added 3 days post-tumor infusion • 1’ CAR-T dose: 5e6 cells • iPSC-CAR-T dose: 30e6 cells
Slide 30: CNTY-101 CAR-iNK cell therapy with Allo-Evasion
CNTY-101 CAR-iNK cell therapy with Allo-Evasion
Slide 31: CNTY-101 clinical program progressing in CARAMEL Phase 1/2 IST
31 CNTY-101 clinical program progressing in CARAMEL Phase 1/2 IST Key Inclusion Criteria: • Participants with moderate to severe SLE, LN, IIM, or dcSSc with treatment-resistant and active disease, after 2+ standard immunosuppressive therapies Key Endpoints: • Safety and tolerability, disease activit
Slide 32: Preliminary Data from the Erlangen CARAMEL Basket Trial
32 Preliminary Data from the Erlangen CARAMEL Basket Trial Preliminary Data Summary 0 20 40 60 0.0 0.5 1.0 1.5 0 20 40 60 0.00 0.05 0.10 0.15 CD19 Pre-CNTY-101 Day 19 Summary N=4 pts dosed Peripheral Blood Lymph Node • 4 patients dosed with CNTY-101 and IL-2 (SLE, IIM, SSc; failed median 7 treatment
Slide 33: Century Therapeutics
CENTURY THERAPEUTICS
Slide 34: Established in-house manufacturing from development to launch
34 Established in-house manufacturing from development to launch Quality product at disruptive scale and cost of goods • Built-for-purpose 53,000 ft2 cGMP facility • Produced and released clinical product for US and EU • Key leaders each with 1–2 decades of cell therapy manufacturing expertise, from
Slide 35: Century Therapeutics Today
Cell Foundry and Allo-Evasion Technology High Impact Programs Focused on Execution Century Therapeutics Today © 2025 35 Cell foundry generates fully functional cells at scale • Key developmental insights allow directed differentiation of cells that function like primary cells, such as beta Islet cel
Slide 36: Century Therapeutics
CENTURY THERAPEUTICS
Century Therapeutics — Investor Presentation (January 2026) on 6ix